Summary
Many human pathologies such as cancer are due to complex biochemical alterations that start at a sub-cellular level and lead to progressive changes that result in a heterogeneous tumor composition. The polyclonality of tumor cells hampers the diagnosis and the therapy giving rise to tumor clones that lead to therapy resistance and promote metastases. An accurate diagnosis of tumor biopsies to identify these particular cell clones is crucial to provide targeted therapy tailored to the tumor characteristics, to improve the patient outcomes and increase survival rates. For this vision to come true, we introduce ulTRafast hOlograPHic FT-IR microscopY (TROPHY) as a paradigm shift in vibrational microscopy, blending elements of photo-thermal infrared (PT-IR), Fourier transform (FT)-IR, and Digital Holography Microscopy (DHM). TROPHY brings these techniques to the unprecedented ultrafast timescale, where the refractive index change induced by coherent IR vibrations is probed at its peak value before thermal relaxation. TROPHY borrows from PT-IR the combination of IR vibrational excitation with visible probing for high spatial resolution, from FT-IR the use of time-domain interferometry to obtain a high spectral resolution from broadband excitation, from DHM highly sensitive and quantitative detection of the refractive index (phase) change. Combined with artificial intelligence algorithms, this technology will enable quantitative concentration imaging of molecular biomarkers with high spatial resolution, high chemical selectivity and high speed, with a transformative impact on medical research and clinics. In oncology, it will be applied to intraoperative diagnosis of tumor biopsies, providing tumor grading, staging and subtyping, and supporting complete tumor resection. It will also allow to determine the best therapeutic approach tailored to the patient and identify resistant tumor clones under targeted therapy, paving the way for precision medicine in cancer.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101047137 |
| Start date: | 01-09-2022 |
| End date: | 28-02-2026 |
| Total budget - Public funding: | 1 904 544,25 Euro - 1 904 544,00 Euro |
Cordis data
Original description
Many human pathologies such as cancer are due to complex biochemical alterations that start at a sub-cellular level and lead to progressive changes that result in a heterogeneous tumor composition. The polyclonality of tumor cells hampers the diagnosis and the therapy giving rise to tumor clones that lead to therapy resistance and promote metastases. An accurate diagnosis of tumor biopsies to identify these particular cell clones is crucial to provide targeted therapy tailored to the tumor characteristics, to improve the patient outcomes and increase survival rates. For this vision to come true, we introduce ulTRafast hOlograPHic FT-IR microscopY (TROPHY) as a paradigm shift in vibrational microscopy, blending elements of photo-thermal infrared (PT-IR), Fourier transform (FT)-IR, and Digital Holography Microscopy (DHM). TROPHY brings these techniques to the unprecedented ultrafast timescale, where the refractive index change induced by coherent IR vibrations is probed at its peak value before thermal relaxation. TROPHY borrows from PT-IR the combination of IR vibrational excitation with visible probing for high spatial resolution, from FT-IR the use of time-domain interferometry to obtain a high spectral resolution from broadband excitation, from DHM highly sensitive and quantitative detection of the refractive index (phase) change. Combined with artificial intelligence algorithms, this technology will enable quantitative concentration imaging of molecular biomarkers with high spatial resolution, high chemical selectivity and high speed, with a transformative impact on medical research and clinics. In oncology, it will be applied to intraoperative diagnosis of tumor biopsies, providing tumor grading, staging and subtyping, and supporting complete tumor resection. It will also allow to determine the best therapeutic approach tailored to the patient and identify resistant tumor clones under targeted therapy, paving the way for precision medicine in cancer.Status
SIGNEDCall topic
HORIZON-EIC-2021-PATHFINDEROPEN-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
